Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock

Core Viewpoint - Jazz Pharmaceuticals is a specialty biopharmaceutical company valued at $11.64 billion, focusing on neuroscience and oncology, primarily generating revenue from sleep disorder drugs Xywav and Xyrem [1][5]. Company Overview - Jazz Pharmaceuticals specializes in neuroscience and oncology, with a significant portion of its revenue derived from its sleep disorder medications [1][5]. - The company has a market capitalization of $11.64 billion and a trailing price-earnings ratio of 44.18x [8]. Stock Performance - Jazz Pharmaceuticals shares have increased nearly 50% over the past year, with a recent trading price of $186.37 [5][6]. - The stock reached an all-time high of $198.00 on February 1 [4]. - Over the past month, the stock is down 0.48% [8]. Technical Indicators - The stock maintains a 100% "Buy" technical opinion from Barchart, with a Weighted Alpha of +55.55 [6][8]. - The Relative Strength Index (RSI) is at 57.73, indicating a strong momentum [8]. - A technical support level is identified around $186.92 [8]. Revenue and Earnings Projections - Revenue is expected to grow by 4.13% this year and by an additional 7.88% next year [8]. - Earnings are estimated to increase by 185.45% this year and by 4.29% next year [8].